The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise
Health
Enrolment: 49 · Results not recorded
Loading the evidence…
Drug · ChEMBL MoA record (via salt CHEMBL1557): beta-1 adrenergic receptor agonist, direct interaction, disease efficacy true. ATC C01CA04 (adrenergic and dopaminergic agent). Approved 1974, parenteral.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Health
Enrolment: 49 · Results not recorded
2 studies reported at therapy level; 2 evidence entries itemised.
Model: Deep hypothermia to a body temperature of 15 C for 3 h followed by 1 h of rewarming under anaesthesia, producing acute kidney injury
Hypothermia and rewarming raised serum creatinine, renal reactive oxygen species, KIM-1 and immune cell influx while lowering renal H2S-producing enzyme expression and serum H2S. Dopamine infusion fully attenuated renal damage and maintained enzyme expression and serum H2S, whereas amino-oxyacetic…
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
Model: Lipopolysaccharide-induced acute lung injury
Dopamine pretreatment reduced lipopolysaccharide-induced oedema and myeloperoxidase activity and increased survival from 0 to 75 percent, acting through the dopamine D2 receptor and the VEGF-VEGFR2 axis; a D2DR agonist failed to reduce oedema in D2DR knockout mice.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.